Skip to content

Effect of treatment using Takra in the management of Grahani Dosha (Irritable bowel syndrome)

A clinical trial to evaluate the effect of specialized treatment protocol using Takra in the management of Grahani Dosha with special reference to Irritable bowel syndrome - STPTGDIBS

Status
Active, not recruiting
Phases
Phase 2Phase 3
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2021/01/030781
Enrollment
30
Registered
2021-01-27
Start date
Unknown
Completion date
Unknown
Last updated
2024-03-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: K582- Mixed irritable bowel syndrome

Interventions

Intervention1: Dadimastaka Churna with Takra Balbilwa Churna and Musta Churna with Takra Panchasakara Churna with warm water: Dadimastaka Churna 6gm with 100 ml of Takra empty stomach Balbilwa Churna

Sponsors

All India Institute of Ayurveda
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1. Patients irrespective of sex, religion, occupation will be selected for study. 2. Patients having pratyatma lakshana of Grahani Dosha especially – Atisrushtam or Ativibadhham or Atidravam malapravritti (altered bowel habits), Trushna, Arochaaka, Vairasya, Praseka, Tamaka, Shoona pada, Shoona kara, Asthi-parva ruja, Chhardi, Jwara, Louha-ama-gandhi tiktamlodgara. 3. The patients who are diagnosed with IBS according to standard ROME IV criteria. 4. Previously diagnosed case of IBS. 5. Able and willing to give written informed consent.

Exclusion criteria

Exclusion criteria: Mixed infection with parasites such as round worms, hook worms etc. 1. Ulcerative colitis, Crohn’s disease, gastric ulcerations and other inflammatory bowel conditions. 2. Infectious disorders like Intestinal tuberculosis etc. 3. Patients with evidence of malignancy. 4. Patents with diabetes mellitus (FBS >126 mg/dl, PP >200 mg/dl), poorly controlled hypertension, Thyroid disorders and any other autoimmune disorders. 5. Amoebic dysentery, acute diarrhoea. 6. Lactose intolerance patients. 7. Abuse of drug or alcohol. 8. Presence of other somatic or mental disorder requiring medication. 9. Patients on prolonged medication with NSAIDs, analgesics or any other drugs that may have an influence on the outcome of the study. 10. History of hypersensitivity to any of the trial drugs or their ingredients. 11. Patients who have completed participation in any other clinical trial during the past 6 months which is interfering with the results of Grahani Dosha. 12. Patients with bleeding per rectum. 13. All the types of atisara, Antraja krimija patients and any other conditions interfering with the results of Grahani Dosha / IBS.

Design outcomes

Primary

MeasureTime frame
Reduction in signs and symptoms of Grahani Dosha by correcting Agni and AmaTimepoint: 0th day, 15th day, 30th day, 60th day

Secondary

MeasureTime frame
1. Nutritional assessment of patient before and after the treatment. 2. To Improvement the quality of life.Timepoint: 0th day, 15th day, 30th day, 60th day

Countries

India

Contacts

Public ContactDr Shivakumar Harti

All India Institute of Ayurveda

drvghuddar@gmail.com9986697942

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026